(Q36915907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Multiple sclerosis: a complicated picture of autoimmunity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Henry F McFarland

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

913-919

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

3 January 2020

cites work

1 reference

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

7 January 2021

Genetics of multiple sclerosis

1 reference

7 January 2021

Understanding the IL-23-IL-17 immune pathway

1 reference

7 January 2021

The IL-23/IL-17 axis in inflammation

1 reference

7 January 2021

Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.

1 reference

7 January 2021

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

7 January 2021

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

1 reference

7 January 2021

Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation

1 reference

7 January 2021

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

1 reference

7 January 2021

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

1 reference

7 January 2021

Development, cytokine profile and function of human interleukin 17-producing helper T cells

1 reference

7 January 2021

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

1 reference

7 January 2021

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

1 reference

7 January 2021

Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate.

1 reference

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

7 January 2021

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis

1 reference

7 January 2021

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

1 reference

7 January 2021

IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production

1 reference

7 January 2021

Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia.

1 reference

7 January 2021

Multiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic Lesions

1 reference

7 January 2021

High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay

1 reference

7 January 2021

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

1 reference

7 January 2021

Experimental autoimmune encephalomyelitis mediated by CD8+ T cells

1 reference

7 January 2021

A pathogenic role for CD8+ T cells in a spontaneous model of demyelinating disease

1 reference

7 January 2021

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

1 reference

7 January 2021

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

1 reference

7 January 2021

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.

1 reference

7 January 2021

CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

1 reference

7 January 2021

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

1 reference

7 January 2021

Immunology of multiple sclerosis

1 reference

7 January 2021

Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis.

1 reference

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

7 January 2021

Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders

1 reference

7 January 2021

Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

1 reference

7 January 2021

Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease.

1 reference

7 January 2021

A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor

1 reference

7 January 2021

High Incidence of Spontaneous Disease in an HLA-DR15 and TCR Transgenic Multiple Sclerosis Model

1 reference

7 January 2021

HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis

1 reference

7 January 2021

Limited repertoire of HLA-DRB1*0401-restricted MBP111-129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential

1 reference

7 January 2021

Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice

1 reference

7 January 2021

Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.

1 reference

7 January 2021

Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis

1 reference

7 January 2021

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

1 reference

7 January 2021

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

1 reference

7 January 2021

A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease

1 reference

7 January 2021

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

7 January 2021

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

7 January 2021

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

1 reference

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

7 January 2021

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

1 reference

7 January 2021

IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program.

1 reference

7 January 2021

Preferential expression and function of Toll-like receptor 3 in human astrocytes

1 reference

7 January 2021

Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis

1 reference

7 January 2021

Regulatory T cells maintain long-term tolerance to myelin basic protein by inducing a novel, dynamic state of T cell tolerance

1 reference

7 January 2021

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells

1 reference

7 January 2021

Mechanisms of suppression by suppressor T cells

1 reference

7 January 2021

Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.

1 reference

7 January 2021

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

7 January 2021

Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients

1 reference

7 January 2021

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

7 January 2021

Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis

1 reference

7 January 2021

Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis

1 reference

7 January 2021

Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells.

1 reference

7 January 2021

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease

1 reference

7 January 2021

Neuroprotection by osteopontin in stroke

1 reference

7 January 2021

Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite

1 reference

7 January 2021

Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis

1 reference

7 January 2021

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

7 January 2021

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

1 reference

7 January 2021

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

1 reference

7 January 2021

Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details.

1 reference

7 January 2021

A novel model of demyelinating encephalomyelitis induced by monocytes and dendritic cells

1 reference

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

7 January 2021

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

7 January 2021

Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis

1 reference

7 January 2021

Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

1 reference

7 January 2021

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

1 reference

7 January 2021

Lack of association between antimyelin antibodies and progression to multiple sclerosis.

1 reference

7 January 2021

Pathological abnormalities in the normal-appearing white matter in multiple sclerosis

1 reference

7 January 2021

Microglial cell activation and proliferation precedes the onset of CNS autoimmunity

1 reference

7 January 2021

Glutamate excitotoxicity in a model of multiple sclerosis

1 reference

7 January 2021

Glutamate inhibition in MS: the neuroprotective properties of riluzole

1 reference

7 January 2021

Identifiers

DOI

10.1038/NI1507

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17712344%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference